$3.25 million in grants to stand up to cancer will improve head and neck cancer treatments
(Stand Up To Cancer) Stand Up To Cancer ® has received $3.25 million in grants from four national nonprofits to fund research to find new treatments for head and neck cancers, which are newly diagnosed in about 65,000 Americans every year. The grants include contributions of $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation. The American Head and Neck Society and the Head and Neck Cancer Alliance each provided $125,000. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Behaviors surrounding oral sex may increase HPV-Related cancer risk
(Johns Hopkins Medicine) A wide breadth of behaviors surrounding oral sex may affect the risk of oral HPV infection and of a virus-associated head and neck cancer that can be spread through this route, a new study led by researchers at the Johns Hopkins Kimmel Cancer Center suggests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news

How Our Sex Habits May Affect Our HPV and Cancer Risk
Certain sex practices, at certain ages, increased the risk of throat cancers related to human papillomavirus. (Source: NYT Health)
Source: NYT Health - January 12, 2021 Category: Consumer Health News Authors: Nicholas Bakalar Tags: Head and Neck Cancer Human Papillomavirus (HPV) Sexually Transmitted Diseases Throat Cancer (Journal) Source Type: news

Researchers create comprehensive database of head and neck cancers
(Johns Hopkins Medicine) Researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news

Head and Neck Cancer Surgery Seems Safe During COVID - 19
Links seen for severe pulmonary complications in COVID - 19 - positive patients with advanced tumor stage, critical care admission (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 29, 2020 Category: Respiratory Medicine Tags: Infections, Oncology, ENT, Pulmonology, Surgery, Critical Care, Journal, Source Type: news

Head and Neck Cancer Surgery Seems Safe During COVID-19
TUESDAY, Dec. 29, 2020 -- Head and neck cancer surgery appears to be safe during the COVID-19 pandemic, according to a study published online Dec. 21 in Cancer. Researchers from the COVIDSurg Collaborative conducted an international, observational... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 29, 2020 Category: Pharmaceuticals Source Type: news

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news

Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Company to Host Investor Conference Call Today at 8:30AM EST PRINCETON, N.J., Dec. 22, 2020 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo... Biopharmaceuticals, Oncology Soligenix, dusquetide, oral mucositis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2020 Category: Pharmaceuticals Source Type: news

Study: COVID-19 rates low among those who have head, neck cancer surgery
Three percent of patients undergoing surgery for head and neck cancer in 26 countries worldwide last spring tested positive for COVID-19 within 30 days of their procedures, according to a study in the journal Cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 21, 2020 Category: Consumer Health News Source Type: news

Study reveals low risk of COVID-19 infection among patients undergoing head and neck cancer surgery
(Wiley) A recent international observational study provides important data on the safety of head and neck cancer surgery during the COVID-19 pandemic. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

NHS England Starts Pilot Trial of Blood Test for Many Cancers NHS England Starts Pilot Trial of Blood Test for Many Cancers
Patients with head and neck, pancreatic, and other hard-to-spot cancers could soon have their disease picked up early with a simple blood test if a pilot by National Health Service (NHS) England is a success.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study: Telemedicine use disparity during COVID-19 among head and neck cancer patients
(Henry Ford Health System) Retrospective research by Henry Ford otolaryngologists found telemedicine use disparity among head and neck cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2020 Category: Cancer & Oncology Source Type: news

Channeling the immune system for head and neck cancer
(University of Cincinnati) University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2020 Category: International Medicine & Public Health Source Type: news

Personalized cancer vaccine clinical trial to expand following promising early results
(University of Arizona Health Sciences) A University of Arizona Health Sciences clinical trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented at the Society for the Immunotherapy of Cancer's annual meeting. Researcher Julie E. Bauman, MD, MPH, reported data on the first 10 patients with head and neck cancer, seven of whom were treated at Banner - University Medicine, clinical partner for the UArizona Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2020 Category: International Medicine & Public Health Source Type: news

Proton Beam and Gabapentin Improve Care in Head and Neck Cancer Proton Beam and Gabapentin Improve Care in Head and Neck Cancer
Proton beam therapy and prophylactic gabapentin each offers significant quality-of-life benefits for patients with head and neck cancer, two studies indicate.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 6, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Proton Beam, Gabapentin Improve Care in Head and Neck Cancer Proton Beam, Gabapentin Improve Care in Head and Neck Cancer
Proton beam therapy and prophylactic gabapentin each offers significant quality-of-life benefits for patients with head and neck cancer, two studies indicate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 6, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Development of a protocol for assessment of suicide risk in patients with head and neck cancer - Anderson JM, Gibbison R, Twigg JA, Kanatas A.
Head and neck cancer (HNC) is the 7th most prevalent cancer globally, with an increasing incidence in recent years which is expected to continue. For many patients, the experience of receiving a diagnosis of HNC and subsequent treatment is disturbing and t... (Source: SafetyLit)
Source: SafetyLit - November 4, 2020 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

PFUA Intake and Head and Neck and Gastric Cancer Incidence PFUA Intake and Head and Neck and Gastric Cancer Incidence
Can dietary intake of dietary long-chain n-3 polyunsaturated fatty acid protect against head and neck or upper GI cancers?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Promising breath-test for cancer
(Flinders University) The global quest to use a person's breath analysis for rapid, inexpensive and accurate early-stage testing for cancer and other diseases has taken a leap forward. In a new paper in the British Journal of Cancer, Flinders University researchers have reported significant progress in developing a method to test exhaled breath profiles which accurately differentiate head and neck cancer from non-cancer patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 5, 2020 Category: Biology Source Type: news

Black lives also matter in cancer care
(University of Colorado Anschutz Medical Campus) It is not biology, but access to health care that is causing Black Non-Hispanic patients with squamous cell cancer of the head and neck to have lower survival rates. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news

Decreasing treatment delays for head and neck cancer patients in South Carolina
(Medical University of South Carolina) Investigators from MUSC Hollings Cancer Center classify barriers to a recommended therapy for head and neck cancer that may mean the difference between life and death for these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 1, 2020 Category: International Medicine & Public Health Source Type: news

US Health Department's Caputo has cancer, spokesperson says
A spokesperson says Trump health appointee Michael Caputo has metastatic head and neck cancer (Source: ABC News: Health)
Source: ABC News: Health - September 24, 2020 Category: Consumer Health News Tags: Health Source Type: news

A Breath Test to Diagnose Head and Neck Cancer A Breath Test to Diagnose Head and Neck Cancer
Breath analysis for non-invasive diagnosis of early-stage head and neck squamous cell carcinoma appears to be practical and accurate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Investor Update - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 2020
Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq ® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address...
Source: Roche Media News - September 19, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

NIDCR Science News - September 2020
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. Shining a Light on Coronavirus Antibodies Repurposed detection method gives glowing results NIDCR • August 19, 2020 Turning Back the Clock on Gum Disease Scientists reverse periodontitis in aged mice NIDCR • July 20, 2020 Scientists Chew on a New Theory of Swallowing Imaging in monkeys reveals ...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news

NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructu...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news

Blood marker may reduce cancer burden
(Flinders University) Researchers at Flinders University are expanding work on a promising blood test model to help predict or diagnose head and neck cancer, a difficult cancer to pick up early and treat.With cancer accounting for almost 10 million a year, the Global Burden of Disease report (2017) attributed more than 380,000 deaths to head and neck cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 1, 2020 Category: Biology Source Type: news

Cephalic Vein for Venous Anastomosis in the Head and Neck Cephalic Vein for Venous Anastomosis in the Head and Neck
In this article, the authors describe a technique which includes harvesting the cephalic vein for venous anastomosis in cases of head and neck cancer reconstruction.ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2020 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

Genetic and Spatial Heterogeneity in Human Papillomavirus-Associated Oropharyngeal Cancer
Joseph Powell will discuss how heterogeneous subpopulations of HPV+ head and neck cancer cells drive unique disease states, cell-cell interactions, and microenvironment dynamics, and have... (Source: The Scientist)
Source: The Scientist - August 20, 2020 Category: Science Tags: Sponsored Webinars Source Type: news

Persistent Hair Loss After Radiation Improved With Minoxidil Persistent Hair Loss After Radiation Improved With Minoxidil
For the first time, a study shows that persistent hair loss after radiotherapy for CNS or head and neck cancer improved with topical minoxidil.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 13, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Study: Topical minoxidil reverses hair loss caused by radiation for brain, head, neck cancers
Treatment with topical minoxidil helps restore hair loss caused by radiation treatment for brain tumors and other head and neck cancers, a study published Wednesday by JAMA Dermatology found. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 5, 2020 Category: Consumer Health News Source Type: news

Characteristics, treatment of radiation-induced hair loss in cancer patients
(JAMA Network) Characteristics and response to treatment of persistent radiation-induced hair loss in patients with primary central nervous system tumors or head and neck cancer were examined in this observational study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 5, 2020 Category: Cancer & Oncology Source Type: news

A normal DNA repair process can become a major source of mutations in cancer
(Institute for Research in Biomedicine (IRB Barcelona)) The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic " cancer driver " mutations, thus accelerating tumour development. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 4, 2020 Category: Cancer & Oncology Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Investor Update - July 31, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq plus Cotellic and Zelboraf for people with advanced melanoma
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.  The safety profile observed in the Tecentriq combination was consistent with the known safety profiles of the individual medicines. The supplemental Biologics License Application (sBLA) for Tecentriq was granted under priority review.   The review was also conducted under Project Orbis, an initiative of the FDA On...
Source: Roche Media News - July 31, 2020 Category: Pharmaceuticals Source Type: news

Precision medicine identifies key recurring mutation in head and neck cancers
(University of California - San Diego) Researchers at UC San Diego School of Medicine and Moores Cancer Center report that an investigational drug candidate called tipifarnib showed promise in treating key recurring mutation in head and neck cancers. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 30, 2020 Category: Biology Source Type: news

Best practice in reducing the suicide risk in head and neck cancer patients: a structured review - Twigg JA, Anderson JM, Humphris G, Nixon I, Rogers SN, Kanatas A.
The treatment of head and neck cancer (HNC) is often radical and the patient's journey challenging, especially for individuals who are struggling with pre-existing mental health problems and who lack social support. Patients frequently suffer from high lev... (Source: SafetyLit)
Source: SafetyLit - July 22, 2020 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
FINDINGSResearchers at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry  have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer.A study in mice found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences and eliminated cancer stem cells. This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminate...
Source: UCLA Newsroom: Health Sciences - July 21, 2020 Category: Universities & Medical Training Source Type: news

Researchers ID new target in drive to improve immunotherapy for cancer
(University of California - Los Angeles Health Sciences) UCLA researchers have identified a potential new combination therapy to treat advanced head and neck squamous cell carcinoma, the most common type of head and neck cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2020 Category: Cancer & Oncology Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news